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Cerebral malaria is characterized by cytoadhesion of Plasmodium falciparum–infected red
blood cells (Pf-iRBCs) to endothelial cells in the brain, disruption of the blood-brain barrier,
and cerebral microhemorrhages. No available antimalarial drugs specifically target the
endothelial disruptions underlying this complication, which is responsible for the majority of
malaria-associated deaths. Here, we have demonstrated that ruptured Pf-iRBCs induce
activation of b-catenin, leading to disruption of inter–endothelial cell junctions in human
brain microvascular endothelial cells (HBMECs). Inhibition of b-catenin–induced TCF/LEF
transcription in the nucleus of HBMECs prevented the disruption of endothelial junctions,
confirming that b-catenin is a key mediator of P. falciparum adverse effects on endothelial
integrity. Blockade of the angiotensin II type 1 receptor (AT1) or stimulation of the type 2
receptor (AT2) abrogated Pf-iRBC–induced activation of b-catenin and prevented the
disruption of HBMEC monolayers. In a mouse model of cerebral malaria, modulation of
angiotensin II receptors produced similar effects, leading to protection against cerebral
malaria, reduced cerebral hemorrhages, and increased survival. In contrast, AT2-deficient
mice were more susceptible to cerebral malaria. The interrelation of the b-catenin and the
angiotensin II signaling pathways opens immediate host-targeted therapeutic possibilities
for cerebral malaria and other diseases in which brain endothelial integrity is compromised.
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Introduction
Cerebral malaria is a multifactorial syndrome involving the interaction 
between Plasmodium falciparum–infected red blood cells (Pf-iRBCs) 
and host cerebral microvascular endothelial cells (1). P. falciparum 
erythrocyte membrane protein-1 (PfEMP1) expressed on the surface 
of iRBCs can bind to several host endothelial receptors of the cerebral 
microvascular bed (endothelial protein C receptor, ICAM-1; refs. 2–4), 
leading to their local sequestration. Disruption of the blood-brain bar-
rier (BBB), ranging from increased permeability to complete loss of 
interendothelial junctions (IEJs) and to petechial hemorrhages in the 
brain, is a characteristic feature of cerebral malaria (5, 6). Available 
antimalarial drugs do not have specific effects against the endothelial 
disruption that occurs during cerebral malaria, for which adjunctive 
treatment is urgently needed. Our aim is to strengthen endothelial 
integrity to protect patients against cerebral malaria pathology while 
conventional antimalarial drugs eliminate the parasite.
Here, we show that rupture of Pf-iRBCs over human brain 
microvascular endothelial cells (HBMECs) induces the activation 
of β-catenin, which mediates the disruption of IEJs in these cells. 
Inhibition of β-catenin activation with modulators of angiotensin II 
(Ang II) receptors protects endothelial cells from Pf-iRBC–induced 
disruption. Some of these modulators, which are approved drugs 
for use in humans, also induce significant protection of mice from 
cerebral malaria. We propose that repurposing of these drugs could 
be used as adjunctive host-targeted therapy for the treatment of 
cerebral malaria.
Results
Pf-iRBCs induce the disruption of IEJs in HBMECs. To study the 
effect of Pf-iRBCs on brain endothelial cells, we first generated an 
immortalized cell line from HBMECs that expresses characteris-
tic endothelial markers and is responsive to tumor necrosis factor 
(TNF) (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI87306DS1), a key player in 
the pathophysiology of cerebral malaria (15). To model the inter-
actions of Pf-iRBCs and brain endothelial cells, HBMEC monolay-
ers were incubated with Pf-iRBCs (3D7) in the schizont stage for 
18 hours (rupture of schizonts is >90% under these conditions). 
The maximal ratio of Pf-iRBCs to HBMECs used was 40:1, which 
represents the ratio necessary to cover the surface of the well at 
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the nucleus when cells are activated (16). Migration of β-catenin 
into the HBMEC nucleus could therefore be indicative of endothe-
lial activation, a process that has been related to the pathology of 
cerebral malaria (17).
We also studied the effect of P. falciparum on endothelial cells 
derived from organs other than the brain. We incubated lung and 
coronary endothelial cell lines with Pf-iRBC schizonts and found 
no significant effects on cellular detachment or translocation of 
β-catenin (Supplemental Figure 2).
Rupture of P. falciparum schizonts is required to induce the 
HBMEC monolayer disruption and migration of β-catenin. To 
determine whether schizont rupture and release of contents is 
necessary to induce HBMEC monolayer disruption, we incubat-
ed schizonts from a P. falciparum line that is conditionally defi-
cient in PfCDPK5, a kinase required for parasite egress (18). We 
observed that arrested schizonts (16.2% rupture) did not induce 
disruption of the HBMEC monolayer (Figure 3A) or migration of 
β-catenin to the nucleus (Figure 3B) compared with control schi-
zonts (99.4% rupture). These indicate that rupture, presumably 
single-layer density, mimicking the pathological accretions of 
Pf-iRBCs observed in vivo in brain capillaries. We observed that 
Pf-iRBCs induce detachment from the substrate of a fraction of 
HBMECs, which are found to be apoptotic or dead in the culture 
media, while virtually all of the remaining attached HBMECs stay 
alive (Figure 1, A–C). A dose-dependent decrease in transendothe-
lial electrical resistance of the HBMEC monolayers was observed 
after incubation with Pf-iRBC schizonts, indicating disruption of 
the endothelial monolayer integrity (Figure 1D). Staining of IEJ 
proteins showed an extensive disruption of these structures result-
ing in the opening of intercellular gaps, and HBMEC detachment 
from the substrate was observed in a dose-dependent manner 
(Figure 2A). HBMECs showed a marked decrease in expression 
of vinculin and ZO-1, which are present in focal adhesions and 
tight junctions, respectively. We also observed higher levels of 
expression of β-catenin, which migrates from adherens junctions 
to the perinuclear and nuclear areas where it accumulates (Figure 
2, A–D). β-Catenin has a dual role in cells, as structural protein in 
IEJs in resting conditions, but also as transcriptional activator in 
Figure 1. Pf-iRBCs induce a dose-dependent detachment from substrate and disruption of IEJs in HBMECs. Monolayers of HBMECs were incubated with 
Pf-iRBCs at the schizont stage or control uninfected RBCs for 18 hours at the indicated ratios of iRBCs to HBMECs or 40:1 for RBCs. (A) Average number 
of HBMECs per microscopic field (n = 10). (B) PrestoBlue determination of viable attached HBMECs. (C) FACS analysis of attached and detached HBMECs 
stained with propidium iodide or annexin V. (D) Transendothelial electrical resistance (TEER) for HBMEC monolayers incubated with Pf-iRBCs (blue) or  
control uninfected RBCs (red) at iRBC/HBMEC ratios of 10:1 (dotted line), 20:1 (dashed line), or 40:1 (continuous line), normalized by TEER of HBMECs 
alone. Results are the average of 6 independent measurements. Results are representative of at least 3 independent experiments. Error bars represent 
±SEM. *P < 0.05, ***P < 0.001 compared with control (1-way ANOVA and Tukey post hoc analysis).
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activation of numerous genes, some of which decrease IEJ stabil-
ity, causing disruption in different cell types (16). To determine 
whether Pf-iRBCs induce the activation of TCF/LEF transcrip-
tion, we transfected HBMECs with a lentiviral vector that carries 
the Tcf promoter linked to a fluorescent reporter for activation 
(TCF-eGFP) (21). Incubation of Pf-iRBCs with HBMECs results in 
strong activation of the Tcf promoter in transfected cells (Figure 4, 
A and B), confirming Pf-iRBC–dependent activation of β-catenin 
in HBMECs. As positive control for β-catenin activation we used 
CHIR-99021, a blocker of the main β-catenin inhibitory regulator 
(glycogen synthase kinase 3β) (16, 22), which induced a lower level 
of activation of β-catenin compared with Pf-iRBCs.
We also investigated whether the activation of β-catenin 
mediates the observed detachment from the substrate and dis-
ruption of IEJs in HBMECs. Using a dominant-negative TCF4 
(dnTCF4) lentiviral vector to inhibit β-catenin–induced transcrip-
tion (21) (Supplemental Figure 4; see complete unedited blots in 
the supplemental material.), we observed that inhibition of TCF/
LEF transcription protects HBMEC monolayers from Pf-iRBC–
induced damage (Figure 4, C–E). These results confirm that Pf-iR-
BC–induced β-catenin activation mediates the detachment from 
the substrate and disruption of IEJs in HBMECs and suggest that 
its inhibition could be explored for therapeutic purposes.
Modulators of Ang II receptors inhibit β-catenin activation and 
disruption of IEJs. To identify inhibitors of β-catenin activation that 
could interfere with P. falciparum–induced effects on HBMECs and 
potentially have a protective effect on the BBB and on the outcome 
of cerebral malaria, we examined the effects of the 2 receptors of 
the vasoactive peptide Ang II, since this pathway regulates vascu-
lar permeability (23) and has also been associated with decreased 
susceptibility to cerebral malaria in human malaria patients (24). 
We first confirmed that Ang II type 1 and type 2 receptors (AT1 
and AT2) are expressed in HBMECs (Figure 5A), before testing 
whether receptor modulators interfere with the activation of β-cat-
enin induced by P. falciparum. Since AT1 and AT2 have counterac-
tive effects in regulating vascular homeostasis and permeability 
through the regulation of IEJs, we chose a receptor blocker of AT1 
(losartan) and an agonist of AT2 (CGP-42112A), which are both 
expected to decrease vascular permeability (25). We observed that 
both losartan and CGP-42112A inhibit the activation of β-catenin 
induced by Pf-iRBCs (Figure 5, B and C) and also prevent HBMEC 
detachment and disruption of IEJs induced by Pf-iRBCs (Figure 5, 
D–H). These results indicate that modulation of Ang II receptors 
interferes with the activation of β-catenin and consequently regu-
lates the stability of the endothelial monolayer.
Modulators of Ang II receptors inhibit cerebral malaria in mice. 
We have used a mouse model for cerebral malaria (P. berghei ANKA 
infection of C57BL/6J mice) to study the effects of Ang II recep-
tor modulators on the permeability of the BBB and susceptibility 
to experimental cerebral malaria during infection. This model 
does not reproduce the mechanism of initiation of human cerebral 
malaria, since P. berghei iRBCs are not cytoadhesive; however, after 
aggregation of blood cells in brain capillaries obstructs circulation, 
the inflammatory environment, endothelial disruption, and BBB 
damage induced are similar to those in human cerebral malaria 
(26, 27), providing an adequate model for our studies, which are 
focused on the protection of the host brain endothelium.
because of the release of merozoites and/or intraerythrocytic 
contents, is required to induce the profound disruption of IEJs 
that we observe in our assay.
Since cytoadhesion of Pf-iRBCs has been proposed to induce 
signaling in endothelial cells through the ePCR receptor, leading 
to IEJ disruption (4), we used the ePCR-cytoadherent P. falciparum 
line (IT4var19; ref. 2) to determine whether this process mediates 
the observed disruption of the HBMEC monolayers. We compared 
the effects of isolated schizonts with knobs (adherent) and without 
knobs (not adherent) from this line (Supplemental Figure 3) and 
found similar effects on HBMECs (Figure 3, C and D). These results 
indicate that rupture, but not cytoadhesion, of P. falciparum schizonts 
is required to induce the observed HBMEC monolayer disruption. 
Signaling through the ePCR receptor and probably others could still 
interfere with the permeability of the endothelium and the integrity 
of IEJs through a pathway different from β-catenin. In the context of 
cerebral malaria, both cytoadhesion, which leads to sequestration of 
schizonts, and the rupture that follows, which would trigger endo-
thelial dysfunction, would be required to induce pathology.
Endothelial cells sense the frictional force of blood flow, which 
activates intracellular signaling and results in the regulation of gene 
expression and cellular behavior (19). After subjecting HBMECs to 
shear stress levels described in the cerebral microvasculature (ζ = 1 
dyn/cm2) (20) before and during the incubation with nonadherent 
Pf-iRBCs, we observed similar results of cellular detachment and 
translocation of β-catenin to the nucleus in HBMECs (Figure 3, 
E–G). These results confirm that flow conditions do not alter the 
effect on HBMECs, but also suggest that a Pf-iRBC–derived soluble 
factor or factors are responsible for this effect.
To further characterize the nature of the Pf-iRBC–derived fac-
tor(s) triggering the disruption of HBMEC monolayers, we collect-
ed the culture medium of Pf-iRBC schizonts after 18 hours of incu-
bation to allow rupture (>90%). After filtration to eliminate intact 
merozoites and aggregated materials from ruptured schizonts, the 
culture medium still preserved the activity to disrupt the endothelial 
monolayer and translocate β-catenin (Figure 3, H and I).
Pf-iRBC–induced disruption of IEJs is mediated by the activation 
of β-catenin. β-Catenin translocation into the nucleus results in 
binding to the TCF/LEF transcription factor complex and trans-
Figure 2. Pf-iRBCs induce disruption of IEJs and migration of β-catenin 
to the nucleus. Monolayers of HBMECs were incubated with Pf-iRBCs at 
the schizont stage or control uninfected RBCs for 18 hours at the indicated 
ratios of iRBCs to HBMECs or 40:1 for RBCs. (A) HBMEC immunostaining 
for the indicated proteins (red or green) and nuclei (blue). Examples of 
opening of intercellular gaps are indicated with arrowheads. Scale bar:  
30 μm. (B) Quantification of fluorescence intensity in arbitrary units (AU) 
for each protein. (C) Confocal analysis of representative HBMECs incubated 
with control RBCs or iRBCs and stained for β-catenin (green) and nuclei 
(blue). Side views show confocal projections of cells on the dashed-line 
axes. Colocalization of nuclear DAPI staining and β-catenin is observed in 
HBMECs incubated with Pf-iRBCs. Scale bar: 10 μm. (D) Quantification of 
β-catenin fluoresce intensity in the perinuclear and nuclear areas versus 
IEJs for each cell in 10 microscopic fields. Results are representative of at 
least 3 independent experiments. Error bars represent ±SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001 compared with control. One-way ANOVA and 
Tukey post hoc analysis for F-actin, β-catenin, and vinculin in B. Krus-
kal-Wallis test and pairwise comparisons using Dunn’s procedure with a 
Bonferroni correction for multiple comparisons for ZO-1 in B and D.
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Mice were infected with P. berghei ANKA and closely mon-
itored for neurological signs. We observed that treatment with 
losartan or CGP-42112A since the first day of infection reduc-
es significantly the incidence of experimental cerebral malaria 
from 75% in the control group to 13.3% and 28.5% in the treated 
groups, respectively. A genetic approach using AT2-deficient 
mice (Agtr2–/– mice) (28) showed that absence of this receptor 
increased susceptibility to experimental cerebral malaria with 
an earlier onset than in controls and 100% incidence (Figure 
6A). Parasitemia in all groups was similar, indicating that the 
protective effect against experimental cerebral malaria is not 
caused by an inhibition of Plasmodium infection (Figure 6B). A 
previous report showed that mice treated with Ang II are more 
resistant to cerebral malaria, but they also present lower levels 
of parasitemia (29) because of the direct toxicity of Ang II to 
Plasmodium (30). This double effect precludes drawing direct 
conclusions about the mechanistic effect of Ang II in experi-
mental cerebral malaria (29).
To confirm that the infected mice had developed experimen-
tal cerebral malaria, as indicated by the neurological signs, brain 
histological sections of each mouse were analyzed for the pres-
ence of hemorrhages that are characteristic of this syndrome. 
We found that every infected mouse, even when protected from 
experimental cerebral malaria, had developed at least a few cere-
bral hemorrhages, confirming the disruption of the BBB (Figure 
6, C–E). However, mice treated with the 2 Ang II receptor modu-
lators presented lower numbers or smaller size of hemorrhages, 
suggesting that the damage to the BBB was mitigated in these 
groups of mice (Figure 6, D and E). Interestingly, AT2-deficient 
mice presented lower numbers of hemorrhages, but of larger size 
than in the control group. Likely, the larger hemorrhages not only 
triggered the early onset of experimental cerebral malaria but 
also prevented further increase in the numbers of hemorrhages 
because of earlier death.
Ang II receptor modulators as adjunctive therapy for cerebral 
malaria in mice. With the aim of investigating the therapeutic 
potential of Ang II receptor modulators for cerebral malaria, we 
modified the mouse model to better represent the conditions of 
patients in the clinic. Only a small percentage of P. falciparum 
infections develop cerebral malaria, but once neurological signs 
have appeared, a high proportion of cases (about 20%) will result 
in death and 10% to 20% of survivors will develop long-term 
neurological sequelae, even if correct antimalarial treatment is 
administered (1). Therefore, treatment for cerebral malaria would 
have to be administered after neurological signs are evident, since 
there are currently no early clinical predictors for the development 
of cerebral malaria. Treatment would be administered in combi-
nation with conventional anti-Plasmodium medication to elimi-
nate the parasite.
For this analysis, we selected an AT1 blocker that is highly 
effective and commonly used for the treatment of hypertension 
(irbesartan; ref. 31) and the only AT2 agonist that is currently in 
clinical development (compound 21; ref. 32). Treatments were 
administered only after the appearance of neurological signs in 
the mice (day 5.5 after infection) and in combination with chloro-
quine. We observed a high increase in survival rates when irbesar-
tan or compound 21 was added, in comparison with control mice 
treated only with chloroquine, in which survival is low (Table 1 and 
Figure 7). It is remarkable to note that a high proportion of mice 
presenting critical neurological signs at the time when adjunc-
tive treatment was started fully recovered from cerebral malaria. 
These results establish the basis for repurposing of Ang II modula-
tors as adjunctive therapy for cerebral malaria.
Discussion
Cerebral malaria is one of the major causes of death in malar-
ia patients; however, the underlying cellular and molecular 
mechanisms causing this pathology remain widely unknown. 
Our findings that (a) rupture of Pf-iRBCs induces the activa-
tion of β-catenin, which leads to the disruption of IEJs in brain 
endothelial cells, and (b) this process is inhibited by Ang II 
receptor modulators establish β-catenin as a key effector of 
P. falciparum in endothelial pathology and open immediate 
therapeutic possibilities.
Cerebral malaria is characterized by the binding of Pf- iRBCs 
to ePCR, ICAM-1, and possibly other molecules, on brain endo-
thelial cells (2–4). This binding recruits high numbers of Pf- 
iRBCs to the brain endothelium, creating a microenvironment 
where circulation is impaired and where release of merozoites 
and erythrocyte components would accumulate as a result of 
natural rupture of Pf-iRBCs at the end of their cycle. Our results 
indicate that rupture of Pf-iRBCs triggers the activation of β-cat-
enin in endothelial cells, but it is likely that binding to ePCR 
and ICAM-1 may also activate β-catenin–independent signaling 
pathways that decrease the integrity of IEJs, as previously pro-
posed (4), ultimately causing the loss of BBB integrity (Figure 8). 
Inflammatory cytokines that increase endothelial permeability, 
such as TNF, could also contribute to this process by destabiliz-
ing IEJs in endothelial cells (33). A combination of these factors 
could lead to vasogenic edema in the brain of cerebral malaria 
patients, potentially leading to brain swelling and death (34). It 
is important to note that regardless of the mechanism inducing 
the disruption of endothelial junctions, the inhibition of β-cat-
enin activation by Ang II modulators is expected to promote IEJ 
stability and increase brain endothelial integrity (35).
Figure 3. Rupture of P. falciparum schizonts, but not cytoadhesion, 
is required to induce the HBMEC monolayer disruption and migration 
of β-catenin. (A and B) Monolayers of HBMECs were incubated without 
parasites (Control) or with D10-PfCDPK5-DDTM P. falciparum schizonts 
(1:40) in the absence (–) or presence (+) of Shield-1 (Shld). The presence 
of Shield-1 allows conditionally CDPK5-deficient arrested schizonts to 
rupture (18). (C and D) HBMECs were incubated alone, with uninfected 
RBCs, or with IT4var19 P. falciparum schizonts (1:40) with or without 
knobs. (E–G) HBMECs were incubated alone, with uninfected RBCs, or with 
3D7 P. falciparum schizonts (1:40) under flow conditions (ζ = 1 dyn/cm2). 
HBMEC immunostaining for β-catenin (green), actin (red), and nuclei (blue) 
is shown in panel E. Scale bar: 30 μm. (H and I) HBMECs were incubated 
alone or with the culture media of ruptured iRBCs. Results are expressed 
as average number of HBMECs per microscopic field (n = 10) in A, C, F, and 
H, and as the quantification of β-catenin fluorescence intensity in the 
perinuclear and nuclear areas versus IEJs for each cell in 10 microscopic 
fields in B, D, G, and I. Results are representative of at least 3 independent 
experiments. Error bars represent ±SEM. *P < 0.05, ***P < 0.001 compared 
with control. Parametric 2-tailed Student’s t test (H and I) or 1-way ANOVA 
and Tukey post hoc analysis were applied (A–D, F, and G).
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Since β-catenin is a major regulator of cellular adhesion (36), 
the connection of this pathway with Ang II receptors links togeth-
er 2 major regulatory pathways in endothelial cells, which has 
important consequences for the understanding of endothelial 
physiology and opens therapeutic possibilities for the regulation 
of brain endothelial integrity and permeability. Our observa-
tions from the in vitro experiments together with the genetic and 
pharmacological approaches in vivo indicate that susceptibility 
Figure 4. Pf-iRBC–induced disruption of IEJs is mediated by the activation of β-catenin in HBMECs. HBMEC monolayers were incubated with  
Pf-iRBCs at the schizont stage or control uninfected RBCs for 18 hours at 40:1 iRBC/HBMEC ratio. (A and B) HBMEC monolayers were infected with  
lentivirus (constitutively expressing mCherry, red) carrying the TCF-eGFP reporter (eGFP, green when activated). Forty-eight hours later, cells were incu-
bated with RBCs, iRBCs, or CHIR-99021 (a positive control for activation of β-catenin; ref. 22). (A) The same microscopic field is shown for eGFP alone and 
merged with mCherry and nuclei. Scale bar: 40 μm. (B) Quantification of eGFP fluorescence per cell. (C–E) Monolayers of HBMECs expressing constitutively 
the TCF-eGFP β-catenin reporter and the mCherry marker were infected or not (Control) with lentivirus carrying dnTCF4 that inhibits β-catenin–induced 
transcription (LV dnTCF4) or an empty lentivirus (LV control). Forty-eight hours later, cells were incubated with Pf-iRBCs. (C) The same microscopic field is 
shown for eGFP alone and merged with mCherry and nuclei. Scale bar: 50 μm. (D and E) Quantification of eGFP fluorescence per cell (D) or number of cells 
per microscopic field (E). Results are representative of at least 3 independent experiments. Error bars represent ±SEM. *P < 0.05, **P < 0.01, ***P < 0.001 
compared with control. One-way ANOVA for the medians in B and D. One-way ANOVA and Tukey post hoc analysis for E.
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ate and 0.5% Albumax II for 3D7 or 10% pooled human serum from 
10 different donors (Interstate Blood Bank Inc.) for IT4var19 at 5% 
oxygen, 5% carbon dioxide, and 90% nitrogen. Parasite cultures were 
synchronized using magnetic separation of late stages with a MACS 
cell separation column (Miltenyi Biotec). To monitor the PfEMP1 
expression in the IT4var19 late-phase parasites, rabbit anti-IT4var19 
DBLa2 serum and a control rabbit serum, both provided by J. Smith 
(Center for Infectious Disease Research, Seattle) (2), followed by 
secondary anti-rabbit–Alexa 488 (111-546-047; Jackson ImmunoRe-
search) were used to stain iRBCs that were analyzed by FACs.
D10-PfCDPK5-DDTM, a gift from J.D. Dvorin (Harvard University, 
Boston, Massachusetts, USA), are transgenic P. falciparum parasites that 
have a destabilizing domain (DD) inserted to regulate the expression lev-
els of PfCDPK5, a kinase that controls parasite egress from erythrocytes 
(18). In the absence of the ligand Shield-1, DD-fused CDPK5 is rapidly 
degraded and parasites are arrested in the schizont stage. The D10-PfC-
DPK5-DDTM line was grown in normal media in the presence of 250 nM 
Shield-1 (Clontech). One day before the experiment, when the culture is 
synchronized in ring stage, medium was changed to the same medium 
without Shield-1. After 24 hours, when parasites in culture were arrested 
in schizont stage, they were separated using a magnetic MACS cell sepa-
ration column. Schizonts were then divided in 2 and incubated overnight 
with a confluent monolayer of HBMECs with or without Shield-1. After 
incubation, medium was recovered and centrifuged at 1,200 g for 5 min-
utes, and the pellet was used to make a smear and stained with Giemsa 
to calculate the percentage of ruptured iRBCs. Effects on the HBMEC 
monolayers were quantified by immunofluorescence of β-catenin and 
determination of number of cells per field.
To produce the culture medium of ruptured Pf-iRBCs, late-stage 
schizonts were resuspended in medium 0.5% FBS at 14 × 106/ml and 
cultured for 18 hours to allow for natural rupture and parasite egress. 
The percentage of rupture was quantified by counting in a hemocy-
tometer. The culture medium was then passed through a 0.22-μm 
nylon filter to remove cellular debris. ECM medium 0.5% FBS was 
added to reach a final concentration of ruptured iRBCs equivalent to 8 
× 106/ml. HBMEC monolayers were then incubated for 18 hours with 
ECM medium 0.5% FBS alone or containing the filtered soluble mate-
rial from 8 × 106 ruptured iRBCs/ml.
Immortalization and culture of HBMECs and other endothelial cell lines
Purified HBMECs were purchased frozen from ScienCell Research 
Laboratories in passage 1, thawed, seeded on culture flasks, and 
grown to confluence in DMEM/F12 medium (pH 7.4) supplemented 
with 10% FBS, 30 mg/ml endothelial cell growth supplement, and 
10 mg/ml penicillin/streptomycin. Cells were incubated at 37°C in 
5% CO2 in water-saturated air. Primary HBMECs in their second pas-
sage from isolation were infected with Lenti-SV40-Ta virus immor-
talization kit (Capital Biosciences). Briefly, cells were infected over-
night in a 6-well plate with 2 ml/well supernatant in the presence of 8 
μg/ml polybrene. After 18 hours, the viral supernatant was discarded 
and fresh culture medium was added to the cells before a 72-hour 
step incubation at 37°C. Cells were then trypsinized and subcultured 
in two 12-well plates for 7 days. Monolayers were then observed 
for growth and morphology changes before being analyzed for the 
expression of SV40 large T antigen by ELISA. The HBEC-4A clone 
was selected for our analyses and was characterized for PECAM-1 
(303101; BioLegend), VE-cadherin (348507; BioLegend), and EPCR 
to experimental cerebral malaria is regulated by Ang II recep-
tors: protection can be achieved by activation of AT2 (with CGP-
42112A) or by blockade of AT1 (with losartan), while the opposite 
effect is observed by deletion of AT2.
Taken together, our results indicate that a shift toward stim-
ulation of the AT2 receptor pathway, which is also achieved 
through the blocking of AT1, inhibits the activation of β-catenin, 
increases the integrity of IEJs, and determines the outcome of 
experimental cerebral malaria.
Another signaling pathway directly implicated in the integ-
rity of brain endothelium is the angiopoietin/Tie2 axis, which 
plays a critical role in endothelial activation and is associated 
with the pathogenesis of cerebral malaria (37). Angiopoietin-1 
via its receptor Tie2 expressed by endothelial cells stabilizes 
the endothelium by promoting endothelial tight junctions, but 
these effects are partially inhibited by angiopoietin-2, resulting 
in endothelial activation and increased vascular permeability 
(38). Several studies have correlated the levels of angiopoietin-1 
and -2 with cerebral malaria severity and survival (37, 39–41). 
Interestingly, a relation between AT1/AT2 activity and angio-
poietin-2 levels has been described in endothelial cells (42, 43), 
possibly mediated by VEGF (44, 45), that may link the activities 
of both pathways in vivo.
Clinicians agree on the need for host-targeted adjunct ther-
apy to rescue patients from death and/or cognitive impairments 
caused by cerebral malaria (46). Strengthening of the IEJs with 
modulators of Ang II receptors could be used as a new strategy 
to develop adjunctive treatments for cerebral malaria that “buy 
time” while conventional anti-Plasmodium drugs eliminate the 
parasite. Therefore, we propose a host-targeted therapeutic strat-
egy based on the reinforcement of brain endothelial cell junctions 
through the inhibition of β-catenin activation. Repurposing of 
AT1 blockers, which are commonly used for treatment of hyper-
tension, as adjunctive treatment for cerebral malaria appears as 
an immediate therapeutic possibility. Blood pressure levels of 
patients would have to be monitored closely during treatment, as 
is done routinely when severe malaria infections are treated with 
quinidine, which also may induce hypotension (47). After its clin-
ical development is completed, compound 21 may also become a 
suitable alternative for treatment, since AT2 agonists would pro-
vide the protective effects mediated by the inhibition of β-catenin 
with lower risk of inducing hypotension (48).
The finding that Ang II receptor signaling inhibits the activa-
tion of β-catenin connects 2 major regulatory pathways in brain 
endothelial cells and suggests that modulators of AT1 and AT2 
may have therapeutic potential for diseases in which the dis-
ruption of endothelial permeability contributes to pathology, as 
recently documented for Ebola infections (49).
Methods
P. falciparum culture
Erythrocytic asexual cultures of P. falciparum 3D7 and IT4var19, a 
gift from J. Smith (Center for Infectious Disease Research, Seattle, 
Washington, USA) (2), were maintained at 5% hematocrit in complete 
medium (RPMI 1640, 25 mM HEPES, 10 μg/ml gentamycin, 0.5 mM 
hypoxanthine, pH 6.75), supplemented with 25 mM sodium bicarbon-
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iRBCs with knobs was recovered, washed with warm medium, and 
passed through a magnetic MACS cell separation column (Miltenyi 
Biotec) to increase purity of late phases. In parallel, the pellet con-
taining knob-negative iRBCs was washed with warm medium, and 
late-phase parasites without knobs were isolated using a MACS cell 
separation column.
Cytoadhesion assays (n = 5) were carried out by coincubation of 
confluent monolayers of HBMECs with iRBCs with or without knobs 
(45 minutes, 37°C) on an orbital shaker (ratio 1:40 HBMECs/iRBCs). 
After incubation, unbound iRBCs were gently washed off 3 times with 
medium. After fixation of cells with 4% paraformaldehyde, adher-
ent iRBCs were determined by counting of 5 random fields per assay 
under ×400 magnification.
Cell viability assay
To assess the viability of adherent HBMECs we used the PrestoBlue Cell 
Viability Reagent (Invitrogen). HBMECs were seeded (1 × 104 cells per 
well) in 96-well plates 24 hours before addition of RBCs or iRBCs and 
the different stimuli (n = 6 per condition). After 18 hours, the plates were 
washed twice with PBS, and PrestoBlue Cell Viability Reagent diluted 
1:10 with medium was added. Samples were then incubated for 3 hours 
at 37°C before measurement of absorbance at 595 nm.
FACS analysis for apoptosis of attached and detached HBMECs was 
carried out with FITC Annexin V Apoptosis Detection Kit I (556547; BD 
Biosciences) according to the manufacturer’s recommended protocol.
Measurements of transendothelial electrical resistance of HBMECs
HBMECs were grown to confluence on gold-plated electrodes in 
96-well array slides linked to a cell-substrate impedance sensing 
system (ECIS; Applied Biophysics). Once a stable measurement of 
resistance from HBMECs was obtained (~1,800 Ω), different concen-
trations of iRBCs and control noninfected RBCs were added, and the 
resistance changes were monitored in real time for up to 32 hours.
Immunofluorescence microscopy
HBMECs were seeded on gelatin-coated glass coverslips at 5.5 × 104 
cells/ml density 24 hours before. Coverslips were fixed with 4% para-
formaldehyde for 10 minutes at room temperature, followed by per-
meabilization with 0.25% Triton X-100 for 10 minutes. Cells were 
preincubated with blocking buffer (PBS, 10% goat serum, 1% BSA, 
100 mM glycine; pH 7.0) for 1 hour at room temperature. Primary rab-
bit antisera (β-catenin, 9587 from Cell Signaling; vinculin, 700062, 
and ZO-1, 339100, from Invitrogen; AT1, AAR-011 from Alomone 
Labs; and AT2 sc-9040 from Santa Cruz) were diluted in blocking buf-
fer and incubated overnight at 4°C. Alexa 488–labeled (111-546-047; 
Jackson ImmunoResearch) or Alexa 594–labeled (A11020; Life Tech-
nologies) secondary anti-rabbit antibodies diluted 1:500 in blocking 
buffer were incubated for 1 hour at room temperature. Rhodamine- 
labeled phalloidin (Invitrogen) was diluted 1:2,000 and incubated for 
10 minutes at room temperature. DAPI (Sigma-Aldrich) at 1 μg/ml was 
incubated for 5 minutes at room temperature. Images were acquired 
and analyzed with MetaMorph Advanced version 7.6.5.0 on an Olym-
pus IX70 inverted microscope.
Confocal microscopy
HBMEC monolayers were imaged with an inverted Leica TCS SP2 
AOBS confocal system (×40 HCX PL APO 1.25–0.75 oil lens) with the 
(351903; BioLegend) by flow cytometry in resting conditions. Also 
cells were analyzed for their response to TNF (BD Pharmingen) (10 
ng/ml) for VCAM (305809; BioLegend) and ICAM-1 (313103; Bio-
Legend) (Supplemental Figure 1). HBMECs were routinely cultured 
in ECM medium with 5% FBS, 1% endothelial cell growth supple-
ment, and 10 mg/ml penicillin/streptomycin (ScienCell).
Human pulmonary microvascular endothelial cells (HPMECs) (50) 
and human coronary artery endothelial cells (HCAECs) (Cambrex Bio 
Sciences) were grown in EBM-2 basal medium (CC-3156) supplement-
ed with EGM-2 MV singleQuot kit that includes 5% FBS and VEGF 
(CC-4147; Lonza). HPMECs (provided by C.J. Kirkpatrick, Johannes 
Gutenberg University, Mainz, Germany) and HCAECs (provided by E. 
Fisher, New York University, New York, New York, USA) were seeded on 
gelatin-coated glass coverslips at 5.5 × 104 and 8 × 104 cells/ml density, 
respectively, 24 hours before incubation with Pf-iRBCs was started.
Flow conditions
HBMECs (160,000 cells) were seeded onto a μ-Slide I Luer0.2 (Ibidi 
GmbH, Germany) and incubated at 37°C and 5% CO2 for 30 min-
utes for cell attachment. Reservoirs in the chamber were then filled 
with supplemented ECM media, and cells were incubated an addi-
tional 2 hours to allow them to form a confluent monolayer. Cells 
were then subjected for 4 hours to flow conditions using a peristaltic 
minipump (Thermo Fisher Scientific). The flow was adjusted to pro-
duce shear stress levels described in the cerebral microvasculature 
(ζ = 1 dyn/cm2) (20). After that time, Pf-iRBCs or uninfected RBCs 
were added to the flow system at the same concentration that is used 
for ratios of 40:1 iRBCs/HBMECs in static-conditions experiments 
(8 × 106/ml) and allowed to circulate for 18 hours before fixation and 
processing for immunofluorescence.
Cytoadhesion assay
IT4var19 parasites were cultured as described above. iRBCs with 
knobs were isolated using gelatin flotation. Briefly, cultured para-
sites were centrifuged 5 minutes at 1,200 g. Pellet was recovered 
and resuspended with 10 volumes of warmed 0.7% porcine gela-
tin (G2625; Sigma-Aldrich) solution in RPMI at 37°C. After 1 hour 
of incubation, the upper phase containing an enriched fraction of 
Figure 5. Modulators of Ang II receptors inhibit Pf-iRBC–induced 
β-catenin activation, detachment, and disruption of IEJs in HBMECs. 
(A) HBMEC monolayers were incubated with specific antibodies against 
AT1 and AT2 receptors followed by a secondary antibody (right panels) or 
with only the secondary antibody (left panels). (B and C) As in Figure 4A, 
HBMEC monolayers were infected with β-catenin reporter lentivirus before 
incubation with iRBCs alone (40:1) or together with losartan (10–5 M) or 
CGP-42112A (10–5 M) for 18 hours. (B) The same microscopic field is shown 
for eGFP alone and merged with mCherry and nuclei. (C) Quantification of 
eGFP fluorescence per cell. (D–H) HBMEC monolayers were incubated with 
Pf-iRBCs, losartan, and CGP-42112A as in B followed (D–G) or not (H) by 
immunostaining for β-catenin (green) and nuclei (blue). (E–G) Quanti-
fication of green fluorescence intensity per cell (E), green fluorescence 
intensity in the perinuclear and nuclear areas versus IEJs for each cell (F), 
and number of cells per microscopic field (G). (H) PrestoBlue determina-
tion of viable attached HBMECs. Results are representative of at least 2 
independent experiments. Scale bar: 40 μm. Error bars represent ±SEM. 
**P < 0.01, ***P < 0.001 compared with control. Kruskal-Wallis test and 
pairwise comparisons using Dunn’s procedure with a Bonferroni correction 
for multiple comparisons.
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(where eGFP expression is driven by a Wnt-responsive cassette) and 
hEF1α-dnTCF4//SV40-PuroR (a dominant-negative form of TCF4) 
viral vectors were a gift from Roel Nusse (Addgene plasmid numbers 
24304 and 24311, respectively). Lentiviruses were produced in 293FT 
cells with plasmids VSVG, pLP1, and pLP2 using the ViraPower Len-
tiviral Packaging Mix from Life Technologies. As a control for the 
dnTCF4 virus, a puromycin-resistant lentivirus (pLKO1) was used as a 
control for mock infection. Expression of the dnTCF4 was confirmed 
by Western blotting (details in Supplemental Information). Lentivi-
following excitation light sources: 405 nm blue diode laser; 488 nm 
argon/krypton line; and HeNe laser lines at 543 nm, 594 nm, and 633 
nm. Bidimensional reconstruction was performed using Leica LCS 
software. Colocalization of nuclear DAPI staining and β-catenin was 
processed in Imaris 7.4 (Bitplan).
Lentivirus production and viral transduction
Lentiviral vectors used to probe the Wnt signaling pathway have been 
previously described (21). The 7xTCF-eGFP//SV40-mCherry (7TGC) 
Figure 6. Modulators of Ang II receptors inhibit experimental cerebral malaria. Groups of WT or AT2-deficient (AT2–/–, black diamonds) C57BL/6J mice 
(n = 38 and 9, respectively) were infected with P. berghei ANKA. Starting on the day of infection, WT mice were treated with losartan (in drinking water 
10 mg/kg/d; n = 15; triangles) or CGP-42112A (administered through intradermal micropumps 500 ng/min/kg; n = 7; squares). Control mice drinking 
regular water (n = 7; black circles) or implanted with intradermal micropumps delivering saline (n = 9; gray circles) were used. (A and B) Survival and mean 
parasitemia. (C–E) Histological sections of the brains of mice were analyzed for the presence (C) and size (D) of hemorrhages. Control group includes mice 
drinking regular water and implanted with intradermal micropumps delivering saline. Center lines show the medians; box limits indicate the 25th and 75th 
percentiles as determined by R software; whiskers extend to minimum and maximum values. (E) Representative microscopic fields. Scale bars: 100 μm. 
Error bars represent ± SEM. *P < 0.05, **P < 0.01 compared with control. Kaplan-Meier and pairwise log rank after Bonferroni correction in A. One-way 
repeated-measures ANOVA for B. One-way ANOVA for the medians in C and D.
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of 3 were considered severe cases and with 4 to 
5 critical cases of cerebral malaria. Mice were 
treated with chloroquine alone (20 mg/kg/d, i.p.; 
Sigma-Aldrich) or in combination with irbesartan 
(50 mg/kg/d, oral gavage; Cayman Chemical Co.) 
or compound 21 (0.3 mg/kg/d, i.p.; provided by 
Vicore Pharma). Treatments were started on day 
5.5 to day 7 after infection, when mice presented 
severe or critical signs, and continued until para-
sitemia was completely cleared (days 11–16 after 
infection) or signs had reached score 5 and includ-
ed paralysis for more than 5 minutes and panting 
(mice were euthanized).
Histopathological studies
In order to analyze the presence of hemorrhages in the brain, paraf-
fin-embedded transverse sections of brain (4 μm thick) were stained 
with H&E and scanned on the Leica Biosystems SCN400 whole-slide 
scanner. The number and maximal diameter of petechiae and hemor-
rhages were quantified in an area of 27.4 ± 1.8 mm2 of brain histological 
sections per mouse using Slidepath Digital Image Hub (DIH) software.
Statistics
To test whether the analyzed variables followed a normal distribu-
tion, all groups were subjected to a normality Kolmogorov-Smirnov 
test. Homogeneity of variances was analyzed by Levene statistic. 
Those variables that confirmed a normal distribution as well as 
the homoscedasticity principle within the different groups were 
further analyzed by parametric 2-tailed Student’s t test or 1-way 
ANOVA test for comparison of the media. Otherwise, the nonpara-
metric Kruskal-Wallis test was applied. When presence of outliers 
was noticed using box plot, robust statistical methods were applied 
to minimize the impact of the outliers in the study (54, 55). Num-
ber and size of hemorrhages of the experimental cerebral malaria 
model were analyzed with robust methods using R statistical soft-
ral supernatants were concentrated using the Lenti-X Concentrator 
from Clontech. Viruses were titrated using 293T cells. HBMECs were 
infected at a multiplicity of infection of 20:1 (lentivirus/HBMECs) in 
culture medium containing 8 μg/ml polybrene. Medium was changed 
the next day before addition of RBCs or iRBCs.
Mice
Female C57BL/6J mice 4 to 6 weeks old were infected by i.p. inocula-
tion of 1 × 106 erythrocytes infected with P. berghei ANKA. Mice were 
monitored twice daily for cerebral malaria signs.
Experiments with losartan and CGP-42112A. AT2 knockout mice 
and their age- and sex-matched WT controls were used from the breed-
ing colony of Thomas Walther at the Forschungseinrichtung für Experi-
mentelle Medizin, Berlin, Germany, and obtained as described (51, 52). 
Mice were considered positive for cerebral malaria when they present-
ed at least 2 of the following signs: ruffled coat, coat starring, panting, 
hemi- or paraplegia, tendency to roll over on stimulation, ataxia, and 
convulsions. Mice with paralysis, convulsions, and/or coma were euth-
anized. This occurred from day 5 to day 9 after infection, depending 
on the individual animals and groups. Mice that did not develop cere-
bral malaria were euthanized on day 9. Immediately after euthanasia, 
brains were collected and washed in cold PBS to remove excess of 
blood and fixed with paraformaldehyde 4% for up to 24 hours and sub-
sequently transferred to ethanol 70%.
Osmotic minipumps (model 1002; ALZA Scientific Products) were 
implanted subcutaneously into C57BL/6J mice at 5 weeks of age. Pumps 
were filled with either saline (vehicle) or CGP-42112A (Sigma-Aldrich) 
that was delivered at 500 ng/min/kg for the duration of the study. 
Pumps were placed into the subcutaneous space of mice anesthetized 
with isoflurane (Henry Schein) through a small incision on the animal’s 
back slightly posterior of the shoulder blades that was closed with Reflex 
7 mm wound closure system (ALZA Scientific Products). All incision 
sites healed rapidly without any further complication. Implantation of 
osmotic minipumps does not alter susceptibility to cerebral malaria or 
parasitemia in mice (29). Losartan (Sigma-Aldrich) was administered in 
the drinking water and adjusted to a final dose of 10 mg/kg/d.
Experiments with irbesartan and compound 21. Female C57BL/6 
mice 4–6 weeks old were purchased from Taconic Laboratories. 
Determination and severity of experimental cerebral malaria were 
scored based on appearance (normal = 0; coat ruffled = 1; coat star-
ring/panting = 2) and neurological involvement (normal = 0; hunched 
= 1; partial paralysis = 2; convulsions = 3). This scoring system is a 
modification of a method described before (53). Mice with a score 
Table 1. Adjunctive therapy with irbesartan (AT1 blocker) or compound 21  
(AT2 agonist) decreases mortality from cerebral malaria in mice
Control Chloroquine Chloroquine + irbesartan Chloroquine + C21
Severe signsA 0B/10C 2/8 3/3 4/4
Critical signsD 0/10 2/14 8/14 7/11
Total survival 0/20 (0%)E 4/22 (18%) 11/17 (65%)F 11/15 (73%)F
AMice with a score of 3. BNumber of surviving mice (complete clearance of parasitemia). CTotal 
number of mice. DMice with a score of 4 to 5. EPercentage of surviving mice. After Bonferroni 
correction, statistical significance was accepted at P < 0.0167. FP < 0.01 compared with 
chloroquine-alone group.
Figure 7. Adjunctive therapy with irbesartan (AT1 blocker) or compound 
21 (AT2 agonist) decreases mortality from cerebral malaria in mice. 
Groups of C57BL/6J mice (see Table 1) were infected with P. berghei ANKA 
and treated with chloroquine alone (n = 22; circles), chloroquine plus C21  
(n = 15; triangles), or chloroquine plus irbesartan (n = 17; squares) after they 
started presenting signs of cerebral malaria (score 3 or higher). **P < 0.01 
compared with chloroquine-alone group. Kaplan-Meier and pairwise log 
rank after Bonferroni correction.
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Figure 8. Proposed model for disruption of IEJs during cerebral malaria. First, cytoadhesion of iRBCs to endothelial receptors congregates high densities 
of iRBCs next to endothelial cells and possibly induces intracellular signaling. After iRBC rupture, release of intraerythrocytic materials triggers the activa-
tion of β-catenin in endothelial cells, which mediates the disruption of IEJs.
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